Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice T Shaw

Showing results (111-120 of 205) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2Lucio Crinò, Myung-Ju Ahn, Filippo De Marinis, et al.
Frontiers in Oncology|July 11, 2025
Young lung cancer: from diagnosis to survivorshipNarjust Florez, Lauren Kiel, Rebekah Kaufman, et al.
The Lancet. Oncology|October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialAlice T Shaw, Enriqueta Felip, Todd M Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation DiversityIbiayi Dagogo-Jack, Marguerite Rooney, Jessica J Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK InhibitorsJessica J Lin, Adam J Schoenfeld, Viola W Zhu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 4, 2023
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 MutationsAlessandra Bearz, Jean-François Martini, Jacek Jassem, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2012
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancerSarah B Goldberg, Jeffrey G Supko, Joel W Neal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancerSai-Hong Ignatius Ou, Lyudmila Bazhenova, D Ross Camidge, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancerRebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2023
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLCRoss A Soo, Jean-François Martini, Anthonie J van der Wekken, et al.
Pageof 21

Showing results (111-120 of 205) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2Lucio Crinò, Myung-Ju Ahn, Filippo De Marinis, et al.
Frontiers in Oncology|July 11, 2025
Young lung cancer: from diagnosis to survivorshipNarjust Florez, Lauren Kiel, Rebekah Kaufman, et al.
The Lancet. Oncology|October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialAlice T Shaw, Enriqueta Felip, Todd M Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation DiversityIbiayi Dagogo-Jack, Marguerite Rooney, Jessica J Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK InhibitorsJessica J Lin, Adam J Schoenfeld, Viola W Zhu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 4, 2023
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 MutationsAlessandra Bearz, Jean-François Martini, Jacek Jassem, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2012
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancerSarah B Goldberg, Jeffrey G Supko, Joel W Neal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancerSai-Hong Ignatius Ou, Lyudmila Bazhenova, D Ross Camidge, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancerRebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2023
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLCRoss A Soo, Jean-François Martini, Anthonie J van der Wekken, et al.
Pageof 21